Literature DB >> 31967071

ADULT OSTEOPOROSIS WITH A HISTORY OF CHILDHOOD-ONSET FRACTURE DUE TO AN LRP5 RECEPTOR VARIANT MUTATION.

Terry Shin, Jay R Shapiro.   

Abstract

OBJECTIVE: This case highlights the value of genetic screening for idiopathic osteoporosis with recurrent fractures.
METHODS: Case report and review of the literature.
RESULTS: A 52-year-old Caucasian female with idiopathic osteoporosis with recurrent fractures was identified with a heterozygous low-density lipoprotein receptor related protein 5 (LRP5) mutation.
CONCLUSION: This case highlights the variability in clinical expression of LRP5 polymorphisms and suggests that standard treatment in cases of recurrent fracture may be ineffective.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31967071      PMCID: PMC6873838          DOI: 10.4158/ACCR-2019-0219.R1

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  14 in total

1.  Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication.

Authors:  José A Riancho; José M Olmos; Begoña Pineda; Carmen García-Ibarbia; María I Pérez-Núñez; Daniel N Nan; Javier Velasco; Antonio Cano; Miguel A García-Pérez; María T Zarrabeitia; Jesús González-Macías
Journal:  Eur J Endocrinol       Date:  2010-10-06       Impact factor: 6.664

2.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

Review 3.  LRP5: From bedside to bench to bone.

Authors:  Bart O Williams
Journal:  Bone       Date:  2017-03-21       Impact factor: 4.398

4.  Idiopathic Juvenile Osteoporosis: Clinical Experience from a Single Centre and Screening of LRP5 and LRP6 Genes.

Authors:  Roberto Franceschi; Monica Vincenzi; Marta Camilot; Franco Antoniazzi; Anthony J Freemont; Judith E Adams; Christine Laine; Outi Makitie; M Zulf Mughal
Journal:  Calcif Tissue Int       Date:  2015-03-18       Impact factor: 4.333

5.  International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

Authors:  A Diez-Perez; K E Naylor; B Abrahamsen; D Agnusdei; M L Brandi; C Cooper; E Dennison; E F Eriksen; D T Gold; N Guañabens; P Hadji; M Hiligsmann; R Horne; R Josse; J A Kanis; B Obermayer-Pietsch; D Prieto-Alhambra; J-Y Reginster; R Rizzoli; S Silverman; M C Zillikens; R Eastell
Journal:  Osteoporos Int       Date:  2017-01-16       Impact factor: 4.507

6.  WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta.

Authors:  Shawna M Pyott; Thao T Tran; Dru F Leistritz; Melanie G Pepin; Nancy J Mendelsohn; Renee T Temme; Bridget A Fernandez; Solaf M Elsayed; Ezzat Elsobky; Ishwar Verma; Sreelata Nair; Emily H Turner; Joshua D Smith; Gail P Jarvik; Peter H Byers
Journal:  Am J Hum Genet       Date:  2013-03-14       Impact factor: 11.025

7.  Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis.

Authors:  Joyce B J van Meurs; Thomas A Trikalinos; Stuart H Ralston; Susana Balcells; Maria Luisa Brandi; Kim Brixen; Douglas P Kiel; Bente L Langdahl; Paul Lips; Osten Ljunggren; Roman Lorenc; Barbara Obermayer-Pietsch; Claes Ohlsson; Ulrika Pettersson; David M Reid; Francois Rousseau; Serena Scollen; Wim Van Hul; Lidia Agueda; Kristina Akesson; Lidia I Benevolenskaya; Serge L Ferrari; Göran Hallmans; Albert Hofman; Lise Bjerre Husted; Marcin Kruk; Stephen Kaptoge; David Karasik; Magnus K Karlsson; Mattias Lorentzon; Laura Masi; Fiona E A McGuigan; Dan Mellström; Leif Mosekilde; Xavier Nogues; Huibert A P Pols; Jonathan Reeve; Wilfried Renner; Fernando Rivadeneira; Natasja M van Schoor; Kurt Weber; John P A Ioannidis; André G Uitterlinden
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

8.  Inactivation of Lrp5 in osteocytes reduces young's modulus and responsiveness to the mechanical loading.

Authors:  Liming Zhao; Joon W Shim; Todd R Dodge; Alexander G Robling; Hiroki Yokota
Journal:  Bone       Date:  2013-01-26       Impact factor: 4.398

Review 9.  Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches.

Authors:  Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2013-08-13       Impact factor: 43.330

10.  Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.

Authors:  Johanna Korvala; Harald Jüppner; Outi Mäkitie; Etienne Sochett; Dirk Schnabel; Stefano Mora; Cynthia F Bartels; Matthew L Warman; Donald Deraska; William G Cole; Heini Hartikka; Leena Ala-Kokko; Minna Männikkö
Journal:  BMC Med Genet       Date:  2012-04-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.